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INTRODUCTION
Postoperative chylothorax is a rare complication in children
who have undergone cardiac surgery for congenital heart
disease. When it occurs, it can contribute to patient’s mor-
bidity or mortality. The general treatment strategy of post-
operative chylothorax is conservative, but surgical reinterven-
tion may be indicated in refractory cases. Lymphatic duct
ligation or pleurodesis has been considered as the proper
surgical intervention (1, 2). With these surgical treatments,
however, problems still remain, and the results are not always
satisfactory. Furthermore, persistent chylothorax may cause
the additional risks to the already compromised patient due
to reopening the chest for lymphostasis. Therefore, a nonin-
vasive treatment for postoperative chylothorax would be bet-
ter for the high-risk patients with congenital heart defect.
Over the last years, an additional conservative treatment op-
tion with somatostatin has been introduced as a new modal-
ity for treatment of postoperative chylothorax (3-5). Thus
far, the results have been mostly reported in the literature as
individual case reports on children. 
In this study, we report our experience in the management
of postoperative chylothorax, with emphasis on the efficacy
of somatostatin therapy in infant and children with chylotho-
rax after cardiac surgery.
MATERIALS AND METHODS
From March 2002 to February 2003, nine patients devel-
oped chylothorax following operations for treatment of con-
genital cardiovascular disease at Samsung Medical Center.
Chylothorax was diagnosed based on the presence of pleural
fluid containing at least one of the following three charac-
teristics: 1) milky appearance; 2) pleural fluid triglyceride
levels greater than 110 mg/mL; 3) lymphocytic predomi-
nance in the fluid cellular component along with sterile cul-
tures (6-8).
The conventional treatment had been undertaken upon
recognition of chylothorax in all patients initially. The con-
ventional treatment consisted of drainage of the pleural space
by thoracentesis or tube thoracostomy, total parenteral nutri-
tion, enteric rest or diet manipulation such as oral fat intake
restricted to medium-chain triglycerides. If the amount of
chylous leakage increased in 2 or 3 consecutive days after the
conventional treatment, then intravenous somatostatin infu-
sion was instituted. The initial starting dose was 3.5  g/kg/
hr and dosage was increased in a stepwise fashion up to 5, 7,
and 10  g/kg/hr and with a maximum dosage of 15  g/kg/
hr. Calories, electrolytes, proteins and clotting factors were
monitored and replaced as necessary. Those patients submit-
ted to cavo-pulmonary procedure (Fontan operation) were
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Somatostatin for Postoperative Chylothorax after Surgery for Children
with Congenital Heart Disease
Chylothorax is a rare but serious postoperative condition with a high rate of morbidity
that may lead to death of children with congenital heart disease. Here we reviewed
nine consecutive cases with chylothorax in infants and children following cardiac
surgery from March 2002 to February 2003. Somatostatin was added to conserva-
tive treatment proctocol to increase effectiveness of therapy in all cases. The dura-
tion of somatostatin therapy varied from 7 to 32 days. All cases of chylothorax were
successfully treated with intravenous infusion of somatostatin as an adjunctive treat-
ment. Even though two cases showed rebound phenomena, we avoided any sur-
gical procedure in the nine patients who treated with conservative management com-
bined with somatostatin. No significant side effects of somatostatin were observed. It
seems that somatostatin is effective, noninvasive and safe therapeutic modality. It
can be used as an adjunctive treatment to conservative management to control
postoperative chylothorax in children with congenital heart disease. 
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also treated with diuretics, inotropes and vasodilators in order
to reduce systemic venous pressure overload. The duration
of somatostatin administration was dependent on the patient’s
response. After cessation of the chylous leakage and resump-
tion of normal dietary habits, we initiated a tapering of soma-
tostatin administration by halving the dosage every day over
a 3-day period. Side effects of somatostatin such as hypoten-
sion, loose stool, and glucose instability were carefully mon-
itored on a regular basis. 
All results are represented as means or median values with
ranges. 
RESULTS
Table 1 shows details of patient, age at time of surgery, the
cardiac diagnosis, the type of operation performed, interval
to diagnosis of chylothorax after cardiac operation and the
maximal drainage volume per day. The patients ranged in
age from 1 week to 4 yr old. They were diagnosed of chy-
lothorax between postoperative day 2 and day 16. The max-
imal daily volume of drainage ranged from 10 to 127 mL/kg
per day. Only one patient (patient 1) experienced chyloperi-
cardium combined with chylothorax. 
Table 2 indicates result of the treatment and the final out-
come for each case. The duration of somatostatin therapy
varied from 7 to 32 days with a median duration of 18 days.
A decrease in drainage was observed at an average of 3.1 days
after the initiation of somatostatin, as the dose of somatostatin
had increased enough to produce an effect (Fig. 1). All cases
of chylothorax were successfully treated with conservative
management combined with intravenous infusion of somato-
statin. The median duration to reduce to 5 mL/kg per day
of lymph drainage was 5 days (range 1 to 25 days). In patient
6 and patient 9, a rebound phenomenon of chylothorax was
noted upon the reduction of somatostatin therapy, but the
rebound effusion responded promptly when the dose of soma-
tostatin was boosted (Fig. 2). No increase in drainage was
observed when their normal diet was resumed. All nine pati-
ents had recovered completely from postoperative chylotho-
rax by the use of somatostatin, and could avoid any invasive
surgical interventions.
Patient 4 
A 3-yr-old girl with a double outlet right ventricle and
atrioventricular septal defect required a Fontan operation.
The postoperative course was complicated by chylothorax
after 3 days of operation. Her chylothorax was managed with
total parenteral nutrition and diet modification firstly. How-
ever pleural effusion persisted. The patient was started on
somatostatin continuous infusion of 3.5  g/kg/hr when her
pleural fluid losses were still 510 mL/day. But the chylous
leak was increased for the next 8 days. At that time, her car-
diac catheterization showed near complete occlusion of supe-
rior vena cava with large thrombus. Because the volume of
daily leakage was up to 1,000 mL and the patient was in an
unstable condition, we decided to attempt an exceptional in-
crease in the somatostatin dose at 15  g/kg/hr before consider-
ing the surgical management. She had a distinguished course
of treatment. The volume of daily chylous leakage was de-
creased dramatically. Chylothorax ceased completely on day
35 without any surgical intervention. In this patient, supe-
rior vena cava syndrome was considered a contributing fac-
Case
No.
Age
(Sex)
Cardiac defect
Type of 
operation
Diag-
nosis
(POD)
Drainage
amount*
1 2 yr 10 mo PA/VSD, DORV Fontan 2 75
(F)
2 4 yr 5 mo Corrected TGA,  Double switch  4 11
(F) VSD, PS operation
3 3 yr 10 mo DILV, VSD, L-TGA,  Fontan 5 10
(M)
4 3 yr (F) AVSD, DORV, Fontan 3 71
5 6 mo (F) AVSD Repair 5 19
6 1 wk (M) DORV, VSD, IAA Repair 12 76
7 1 wk (M) PA/VSD, PDA RMBT 16 30
8 3 mo (M) AVSD, SV, PA,  RMBT,  11 29
TAPVR, MAPCA TAPVR repair,
MAPCA 
unifocalization
9 2 wk (F) TGA, VSD ASO 16 127
Table 1. Characteristics of patients with chylothorax
ASD, atrial septal defect; ASO, arterial switch operation; AVSD, atrioven-
tricular septal defect; DILV, double inlet left ventricle; DORV, double out-
let right ventricle; IAA, interruption of aortic arch; MAPCA, major aortopul-
monary collateral arteries; PA, pulmonary atresia; PDA, patent ductus
arteriosus; POD, post operative day; PS, pulmonary stenosis; RMBT,
right modified Blalock-Taussig shunt; SV, single ventricle; TAPVR, total
anomalous pulmonary venous return; TGA, transposition of great arter-
ies; VSD, ventricular septal defect.
*, maximal daily drainage (mL/kg/day).
Case
No.
Dura-
tion
1
Dura-
tion
2
Re-
bound
pheno-
mena
Side-
effect of
somao-
statin
Outcome
1 26 11 - None Successful CM
2 15 1 - None Successful CM
3 15 5 - None Successful CM
4 32 25 - None Successful CM
5 17 4 - None Successful CM 
6 26 14 - None Successful CM
7 18 5 - None Successful CM
8 7 1 - None Successful CM
9 30 19 + Loose stool Successful CM
Table 2. Outcomes of patients with somatostatin therapy
Duration 1, duration of somatostatin therapy (day); Duration 2, duration
to reduction of chylous leakage to 5 mL/kg/day (day); CM, conservative
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tor for the prolonged chylous drainage, but the high dose
somatostatin infusion was tolerated for 21 days without any
apparent side effects (Fig. 3).
Patient 9 
10-day-old girl born with transposition of great arteries
and ventricular septal defect underwent arterial switch oper-
ation and closure of ventricular septal defect. On postopera-
tive day 9, she had second operation for wound debriment
and repair of surgical wound. After that day, drainage from
chest tube became large up to 300 mL/day, when her chy-
lothorax was confirmed. Her chylous drainage was persis-
tent after conservative managements, so we added infusion
of somatostatin. Her chylous leakage decreased to 40 mL/
day by postoperative day 32. She developed loose stool for 2
days during the infusion of somatostatin, but the diarrhea
spontaneously resolved. Aside from this, there were no appar-
ent adverse effects of the somatostatin. 
DISCUSSION
Chylothorax is a rare, but potentially serious complication
of pediatric cardiac operations. It was estimated to occur at
an incidence of 0.25% to 0.8% following cardiovascular pro-
cedures (9, 10). The standard treatment for postoperative
chylothorax includes conservative therapy with pleural space
evacuation, enteric rest or fat-free nutrition, and total parenteral
nutrition (11). If this is not successful, operative treatment
such as pleurodesis, ligation of the thoracic duct and pleu-
roperitoneal shunt is indicated (12, 13). However, these sur-
gical treatments have some limitations. Pleurodesis is a painful
procedure and the long-term results can vary. Ligation of the
thoracic duct may fail as a result of anatomic variations of
the thoracic duct or due to a failure for identifying the chy-
lous leakage sites (6). 
There have been several anecdotal reports in the literature
related to using somatostatin for treating chylothorax as a
complication of thoracic procedures in adults (3-5). Somato-
statin is a peptide hormone that acts as a neurohormone as
well as a paracrine agent, and it is present in the central ner-
vous system, gastrointestinal tract and pancreas (14). The
exact mechanisms involved for the drying effect of somato-
statin on lymphatic leakage are not wholly understood. The
effectiveness of somatostatin may be due to its ability to de-
crease the hepatic venous pressure gradient, to decrease the
intestinal absorption of fats, to decrease the triglyceride con-
centration in the thoracic duct and to attenuate splanchnic
blood flow (15-17). In addition, it could be that the lym-
phatic vessels contain somatostatin receptors, like the blood
vessels in the splanchnic area, and that their constriction
reduces the lymph production (18, 19).
In 1998, Rimensberger et al. (20) reported the successful
use of somatostatin in children to control increasing chylous
drainage under conservative treatment. In addition, the authors
described several pediatric cases of postoperative chylotho-
rax that were treated with somatostatin (21-23). In our study,
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Fig. 1. Clinical course of patient number 3.
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3 patients underwent surgical procedure for their congenital
heart disease during the neonatal period. In our cases, no seri-
ous complications associated with unabated chylous drainage
were encountered, which is in contrast to the previous reports
(21, 22). This is probably due to the prompt use of intrave-
nous somatostatin after the diagnosis of chylothorax during
the postoperative period.
Opinions vary in the literature regarding the appropriate
dose and type of administration for somatostatin for children
with postoperative chylothorax. The starting dose was 3.5
g/kg/hr according to the case report of Rimensberger et al.
(20). Buettiker et al. suggest that chyle production began
cessation at a dose of 10  g/kg/hr, but they also tried increas-
ing the dose up to 12  g/kg/hr for chylothorax refractory to
the conventional dose (21). In our study, we increased the
dosage of somatostatin up to 15  g/kg/hr in one case with-
out observing any serious side effects. Somatostatin is currently
used for the therapy of diverse pediatric diseases such as acro-
megaly, intractable diarrhea and gastrointestinal bleeding
(24-29). Because this therapy is still experimental, further
studies that take into consideration the duration and tolera-
ble dosages are necessary to assess the safety of its adminis-
tration in children.
Superior vena cava thrombosis is also well known to be a
risk factor for the failure of non-operative management of
chylothorax (1). It is usually recommended that such patients
be considered for earlier operative intervention when this com-
plication is associated with chylothorax. In our case, however,
the patient’s poor general condition led us to attempt somato-
statin trial before any invasive steps. The satisfactory outcome
in this patient may be speculated as the results of somatostatin
and/or the development of collateral lymphatic channels.
The side effect of somatostatin is primarily related to the
suppressed actions of gastrointestinal motility and secretion,
and this includes hypotension, loose stool, malabsorption,
nausea, flatulence, liver dysfunction and hyperglycemia (15).
In all 9 patients, no significant side effects were observed
that necessitated medical intervention or discontinuation of
somatostatin. 
The results of our case series are suggesting the value and
safety of somatostatin in pediatric patients with postopera-
tive chylothorax. The continuous infusion of somatostatin
may be of particular benefit if the patient is in a poor general
condition, and additional risks may be introduced with repeat-
ed surgery. A larger prospective study needs to be undertaken
to verify our investigations.
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